These CD38-/- NK cells also demonstrate enhanced ADCC activity against MM cell lines with low CD38 expression and MM cells obtained from a non-responsive daratumumab (DARA)-treated patient, compared to CD38 wild-type NK cells. This evidence concerns the gene CD38 and Miyoshi myopathy.